Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06216886 · ClinicalTrials.gov registry record · Phase 4
OnabotulinumtoxinA for Trigeminal Neuralgia
A Phase 4 study of Trigeminal Neuralgia, sponsored by Stanford University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06216886: Recruiting Phase 4 study of Trigeminal Neuralgia, sponsored by Stanford University.
NCT06216886 is a Phase 4 study of Trigeminal Neuralgia that is actively recruiting participants, run by Stanford University. The registered enrollment target is 20 participants, below the 5,768-participant average among 9 other Trigeminal Neuralgia trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06216886, a Phase 4 study of Trigeminal Neuralgia, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
A randomized controlled trial comparing Onabotulinumtoxin A to saline (placebo) for Trigeminal Neuralgia.
Primary Outcome
Frequency of TN attacks before and after onabotA injection over a seven day period
Conditions Studied
Interventions
- DRUG OnabotulinumtoxinA 100 UNT [Botox]
- DRUG Sodium Chloride 0.9% for Injection, Preservative Free
Study Locations (1)
California
- Meredith Barad - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-06-01 |
| Est. Completion | 2027-09-01 |
| Phase | Phase 4 |
What NCT06216886 shows while recruiting
NCT06216886 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 5,768-participant average among 9 other Trigeminal Neuralgia trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Trigeminal Neuralgia appearing as the primary indexed condition, and to 2 interventions - of which OnabotulinumtoxinA 100 UNT [Botox] is the first listed.
NCT06216886 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06216886 about?
NCT06216886 is a clinical study titled "OnabotulinumtoxinA for Trigeminal Neuralgia". A randomized controlled trial comparing Onabotulinumtoxin A to saline (placebo) for Trigeminal Neuralgia.
What is the current status of trial NCT06216886?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2024-06-01. Estimated completion is 2027-09-01.
What conditions does trial NCT06216886 study?
This clinical trial studies the following conditions: Trigeminal Neuralgia.
What interventions are being tested in trial NCT06216886?
The interventions under investigation include: OnabotulinumtoxinA 100 UNT [Botox] (DRUG), Sodium Chloride 0.9% for Injection, Preservative Free (DRUG).
Who is sponsoring clinical trial NCT06216886?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06216886 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Trigeminal Neuralgia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06216886's enrollment target sits among peer trials
20 9th of 9 higher than 1 of 9 other Trigeminal Neuralgia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Trigeminal Neuralgia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Will Erwin Headache Research Center - Cluster Headache Study
RECRUITING
-
RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT
RECRUITING
-
Trigeminal Evoked Responses to Improve Rhizotomy
RECRUITING · Early Phase 1
-
Trigeminal Neuralgia Electrophysiology
RECRUITING
-
RAD 1501: A Trial of Virtual Cone Trigeminal Neuralgia Radiosurgery
ACTIVE NOT RECRUITING · NA
-
Transcranial Magnetic Stimulation for Chronic Neuropathic Pain
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI